Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination of ferric pyrophosphate citrate and unfractionated heparin** administered intravenously during hemodialysis. Ferric pyrophosphate citrate is an iron replacement agent designed to maintain iron balance by providing soluble iron, which is rapidly chelated by transferrin and incorporated into hemoglobin for erythropoiesis, bypassing the macrophage-mediated iron sequestration seen with traditional IV iron[1][3]. Unfractionated heparin is an anticoagulant that enhances the activity of antithrombin III, inactivates thrombin and factor Xa, and is widely used in dialysis to maintain circuit patency. Clinical studies confirm **no significant pharmacokinetic or pharmacodynamic drug-drug interactions when ferric pyrophosphate citrate is co-administered with unfractionated heparin as a single admixture, and each retains its efficacy and safety profile for iron delivery and anticoagulation**[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferric pyrophosphate citrate + heparin.